ⓘ International Ovarian Tumor Analysis trial


ⓘ International Ovarian Tumor Analysis trial

The International Ovarian Tumor Analysis group was formed in 1999 by Dirk Timmerman, Tom Bourne, and Lil Valentin. Its first aim was to develop standardised terminology, and in 2000 IOTA published a consensus statement on terms, definitions and measurements to describe the sonographic features of adnexal masses that is now widely used today. IOTA now comprises one of a portfolio of studies examining many aspects of gynaecological ultrasonography and early pregnancy within a network of contributing centres throughout the world that are co-ordinated from KU Leuven

Having agreed on standardised terminology the principal iota investigators prospectively studied a large cohort of patients with a persistent adnexal mass in different clinical centers. The database of the Department of civil engineering at the Catholic University of Leuven were included as previously developed prediction models must be verified and new prediction models must be developed and validated from the outside. Therefore bit managed to clarify the optimal approach to characterize abdominal pathology in the preoperative period. Iota simple rules also described on the basis of ultrasound, which can be used for the classification of ovarian cysts and therefore, the diagnosis of "ovarian cancer". They can be applied in about 75% of the mass. For the rest, still scanning the sub-specialist recommended by the manufacturer. Another approach is to use simple descriptors, which are intuitive features of the mass that the ultrasound expert can use to easily classify about 50% by weight. A short description of the iota studies were published as comments.

Currently, Yota is engaged in several new elements. Group studying long-term behavior of expectantly managed adnexal iota phase pathology 5. This will allow us to answer important questions about complications and malignant transformation of the mass that remained in place. A number of studies carried out on masses that currently are difficult to classify even the most experienced expert. These studies involve the use of vascular imaging, proteomics, new biomarkers and MRI to name just a few of the iota phase 3. Finally, clinical trials are held in London the Iota phase 4 to assess the effectiveness of iota prediction models and rules in the hands of experts with different levels of experience and training. Two documents were published with the Iota 4 studies, which suggest that iota rules and models to work when they are not applied by experts.

Today there are over 50 clinical departments to assist in the study of the iota in almost every continent. The culture of Iota should be transparent and open to new employees. The group is multidisciplinary and includes gynecologists, radiologists, oncologists and physicists, and biologists. The group believes that good communication between all these disciplines as ideas can be turned into improvements for patients. 2013 marked new developments for iota. Particular attention was paid to the research group spent the first iota Congress and the development of the iota website. Installing platform clinical research centers Iota will be planning further study examining aspects of treatment of ovarian cancer and prognosis. Interested units should contact the group and we are always interested in new ideas!

  • Ben Timmerman, Dirk August 2012 Key findings from the International Ovarian Tumor Analysis IOTA study: an approach to the optimal ultrasound based
  • APL Iota and Jot, two esoteric programming languages International Ovarian Tumor Analysis trial and group, founded to develop standardized terminology
  • A tumor marker is a biomarker found in blood, urine, or body tissues that can be elevated by the presence of one or more types of cancer. There are many
  • possibility for males having testicular tumors and the Turner syndrome TS affects the risk of having ovarian cysts in females. Swyer syndrome and other
  • is a tumor of germ cell origin, containing tissues from more than one germ cell line. It can be ovarian or testicular in its origin. An ovarian teratoma
  • predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials - Keshaviah et al. 18 4 701 - Annals of
  • apoptosis inducer Fas ligand FasL that is found in the tumor vasculature of tumor types including ovarian colon, prostate, breast, bladder and renal cancer
  • 2013 - 04 - 01 Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case - control studies International Journal of Epidemiology. 42 2 579 589
  • Roughly 15 of ovarian cancers are detected at the early stage, at which the 5 - year survival rate is 92 A Norwegian meta - analysis of 22 randomized